Trial reportBMC complementary and alternative medicine2019
Immunomodulatory effects of a mycelium extract of Cordyceps (Paecilomyces hepiali; CBG-CS-2): a randomized and double-blind clinical trial.
Trial report in BMC complementary and alternative medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- A randomized controlled clinical trial examining the effects of Cordyceps militaris beverage on the immune response in healthy adults.Scientific reports · 2024Trial
- Effects ofNutrients · 2020Trial
- Medicinal Mushrooms and Their Bioactive Compounds: From Traditional Use to Therapeutic Potential.Molecules (Basel, Switzerland) · 2026Review
- Pleiotropic Bioactivity of Caterpillar Fungus, Orange Cordyceps, and Cordycepin: Insight from Integrated Network Pharmacology and Food and Drug Regulatory Framework.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The GenusLife (Basel, Switzerland) · 2025Review
- Preclinical Evidence ofInternational journal of molecular sciences · 2025Review
- The Benefits and Applications ofIranian journal of public health · 2024Review
- Article biodiversity inside bottles: animals, fungi, and plants in traditional alcoholic drinks.Frontiers in nutrition · 2024Review
- Unique Bioactives from Zombie Fungus (Nutrients · 2023Review
- Early Trends to Show the Efficacy of Cordyceps militaris in Mild to Moderate COVID Inflammation.Cureus · 2023Article
- Natural Ingredients to Improve Immunity.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Effects of Cordyceps militaris fermentation products on reproductive development in juvenile male mice.Scientific reports · 2022Article
- Cordycepin Protects against Hepatic Ischemia/Reperfusion Injury via Inhibiting MAPK/NF-Mediators of inflammation · 2022Article
- Cordycepin Induces Apoptosis through JNK-Mediated Caspase Activation in Human OEC-M1 Oral Cancer Cells.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Cordycepin Sensitizes Cholangiocarcinoma Cells to Be Killed by Natural Killer-92 (NK-92) Cells.Molecules (Basel, Switzerland) · 2021Article
- Article
- Substantial involvement of TRPM7 inhibition in the therapeutic effect of Ophiocordyceps sinensis on pulmonary hypertension.Translational research : the journal of laboratory and clinical medicine · 2021Article
- An overview on natural farnesyltransferase inhibitors for efficient cancer therapy.Journal of enzyme inhibition and medicinal chemistry · 2020Review
- Natural products as home-based prophylactic and symptom management agents in the setting of COVID-19.Phytotherapy research : PTR · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCordyceps is a traditional Chinese herb that produces various biopharmaceutical effects, including immune-enhancing effects. In this study, we prepared a Cordyceps mycelium culture extract (Paecilomyces hepiali, CBG-CS-2) to confirm its efficacy in enhancing the immune system and to evaluate its safety in healthy adults.
methodsHealthy adults were divided into the intervention group (n = 39), who were given 1.68 g/day of CBG-CS-2 in capsules, and the control group (n = 40) for 8 weeks. The activities of natural killer (NK) cells and serum levels of monocyte-derived mediators were assessed initially for a baseline measurement and after 8 wks.
resultsThe CBG-CS-2 group showed a significant 38.8 ± 17.6% enhancement from the baseline of NK cell cytotoxic activity relative to the placebo group after the administration of the capsules for 8 wks. (P < 0.019).
conclusionThe results suggest that the immune system functions well with CBG-CS-2 supplementation, perhaps with less accompanying inflammation. Thus, CBG-CS-2 is safe and effective for enhancing cell-mediated immunity in healthy adults.
trial registrationThis study was registered at Clinical Trials.gov ( NCT 02814617 ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.